Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001193125-23-273614 0001737428 XXXXXXXX LIVE 4 Class A Common Stock, par value $0.01 10/03/2025 false 0001723128 03168L105 Amneal Pharmaceuticals, Inc. 400 Crossing Blvd Bridgewater NJ 08807 Christine Krentz (908) 409-6700 4 Gatehall Drive Parsippany NJ 07054 0001737428 Patel Chintu a OO X1 25910032 0 25910032 0 25910032 N 8.2 IN The percentage of ownership of the Class A Common Stock by the Reporting Person presented in this Statement is based on 314,079,309 shares of Class A Common Stock outstanding, as disclosed in the New Issuer's Quarterly Report on Form 10-Q, filed on August 7, 2025. Class A Common Stock, par value $0.01 Amneal Pharmaceuticals, Inc. 400 Crossing Blvd Bridgewater NJ 08807 This Amendment No. 4 to Schedule 13D (this "Amendment No. 4") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 4, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the New Issuer. Capitalized terms used but not defined in this Amendment No. 4 shall have the meanings set forth in the Schedule 13D. On October 3, 2025, the Reporting Person caused a trust controlled by the Reporting Person (the "Trust") to contribute, without consideration, 13,257,287 shares of Class A Common Stock to Shivkan Holdings X, LLC, a Delaware limited liability company ("Shivkan"). The Trust is the sole member of Shivkan. The purpose of these transactions was to facilitate the transactions described in Item 6 below. The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Class A Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 314,079,309 shares of Class A Common Stock outstanding, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed on August 7, 2025: Reporting Person: Chintu Patel Amount beneficially owned: 25,910,032 Percent of class: 8.2% Sole power to vote or to direct the vote: 25,910,032 Shared power to vote or to direct the vote: 0 Sole power to dispose or to direct the disposition: 25,910,032 Shared power to dispose or to direct the disposition: 0 The Reporting Person owns directly (i) 864,033 shares of Class A Common Stock, (ii) 24,977 shares of Class A Common Stock issuable upon exercise of options exercisable for $15.01 per share, which expire on May 7, 2028; (iii) 28,044 shares of Class A Common Stock issuable upon exercise of options exercisable for $14.05 per share, which expire on May 6, 2029; and (iv) 239,726 shares Class A Common Stock issuable upon the vesting and settlement of restricted stock units. The Reporting Person may be deemed to beneficially own 11,495,965 shares of Class A Common Stock held of record by trusts controlled by the Reporting Person and 13,257,287 shares of Class A Common Stock held of record by Shivkan. The information set forth in Item 4 and Item 6 of this Amendment No. 4 is incorporated by reference herein. The information set forth in Item 4 and Item 6 of this Amendment No. 4 is incorporated by reference herein. Not applicable. Item 6 of the Schedule 13D is hereby amended and supplemented by adding the following information. On October 3, 2025, Shivkan entered into a Margin Loan Agreement (the "Margin Loan Agreement") with Citibank, N.A. ("Citibank"). In connection therewith, Shivkan agreed to pledge to Citibank 13,257,287 shares of Class A Common Stock (the "Collateral") to secure the obligations of Shivkan under the Margin Loan Agreement, pursuant to a Pledge and Security Agreement, dated as of October 3, 2025, by and between Shivkan and Citibank (the "Security Agreement" and, together with the Margin Loan Agreement, the "Loan Documents"). The obligations of Shivkan under the Margin Loan Agreement mature on April 5, 2027. Upon the occurrence of certain events that are customary with this type of transaction, Citibank may exercise its rights to foreclose on, and dispose of, the Collateral in accordance with the Loan Documents. In order to facilitate the exercise by Citibank of its rights upon the occurrence of any such event, the Issuer also entered into an Issuer Letter Agreement, dated as of October 3, 2025, with Citibank (the "Issuer Agreement"). Copies of the Security Agreement and the Issuer Agreement are attached as Exhibits to this Schedule 13D, and are incorporated herein by reference. Except as set forth herein, the Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies. 5. Pledge and Security Agreement, dated as of October 3, 2025, by and between Shivkan and Citibank. 6. Issuer Letter Agreement, dated as of October 3, 2025, by and between Shivkan and Citibank. Patel Chintu Chintu Patel Patel Chintu 10/07/2025